Biotechs lured overseas by incentives and specialists

Two of Australia’s largest biotechnology companies are looking at ways of tapping into the greater valuations accorded to the sector overseas, presenting policy makers with challenges in keeping some high technology areas. One of the largest of the locally grown biotech companies, Mesoblast, is believed to be considering a sharemarket listing in the US, in a bid to lift its sharemarket valuation. Read more

« »

Lead Partners

NZTE NZGCP PWC “NZX” Callaghan Innovation

Expert Partner

AVID “Jarden”

AANZ Summit Sponsors

“UniServices” Kiwinet “AWS” “BNZ” “Momentum” “Punakaiki” “MBIE” “GD1” “WellingtonUniVentures” “Movac”